MICHAEL MILLIKEN: Open Payments
NPI 1629275037 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 19 payments from 11 companies in 2025. Trend: 2023 $2,359 · 2024 $518 · 2025 $499
Food & beverage: $400Education: $99
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $146 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| UCB, Inc. | 2 | $53 |
| Janssen Biotech, Inc. | 2 | $52 |
| ABBVIE INC. | 2 | $49 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| PFIZER INC. | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: DUPIXENT, COSENTYX, Bimzelx, TREMFYA, SKYRIZI, Zoryve, LITFULO, OPZELURA.
Industry payments across TX — which companies pay providers there.
